Permethrin
FDA-approved product (lotion, topical), marketed as Elimite, Nix, Permethrin.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Parasitic infection
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Pyrethrines, incl. synthetic compounds
- FDA pharmacologic class
- Pyrethroid FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P03AC04; WHO ATC P03AC54
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Permethrin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Quinapril HydrochlorideExisting use: Cardiovascular disease, Diabetes mellitus, Heart failure and 3 more62.3% AI-predicted activityagainst M. tuberculosis33 registered studies
- BelzutifanExisting use: Clear cell renal carcinoma, Hemangioblastoma, Neoplasm and 4 more62.2% AI-predicted activityagainst M. tuberculosis45 registered studies
- ChlorprothixeneExisting use: Psychosis62.2% AI-predicted activityagainst M. tuberculosis4 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis62.2% AI-predicted activityagainst M. tuberculosis2 registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more62.1% AI-predicted activityagainst M. tuberculosis44 registered studies
- Methdilazine HydrochlorideExisting use: Allergic disease62.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more62.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma61.9% AI-predicted activityagainst M. tuberculosis40 registered studies
- TrandolaprilExisting use: Cardiovascular disease, Heart failure, Hypertension and 2 more61.9% AI-predicted activityagainst M. tuberculosis29 registered studies
- Almotriptan MalateExisting use: Migraine disorder61.8% AI-predicted activityagainst M. tuberculosis16 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Metabolism of the Insecticide Permethrin
NCT00572884 · start 2006-02
Registered record
- Registry ID
- NCT00572884
- Conditions
- Pharmacokinetics; Metabolism
- Interventions
- permethrin insecticide
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-02
- Completion
- 2007-11
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPharmacokinetics; MetabolismInterventionpermethrin insecticidePhaseNot applicableRegistry statusCompletedSafety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
NCT00244439 · start 2005-12
Registered record
- Registry ID
- NCT00244439
- Conditions
- Lice Infestations
- Interventions
- MALG; Ovide (malathion) lotion 0.05%; Permethrin 1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2006-12
- Enrolment
- 360
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLice InfestationsInterventionMALG; Ovide (malathion) lotion 0.05%; Permethrin 1%PhasePhase 3Registry statusCompletedComparison of the Efficacy and Safety of Ivermectin to Permethrin
NCT00262418 · start 2004-07
Registered record
- Registry ID
- NCT00262418
- Conditions
- Scabies
- Interventions
- Administration of ivermectin or permethrin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-05
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScabiesInterventionAdministration of ivermectin or permethrinPhasePhase 2Registry statusCompletedEffect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
NCT00347763 · start 2000-06
Registered record
- Registry ID
- NCT00347763
- Conditions
- Trachoma
- Interventions
- 10% permethrin in water applied as low volume spray
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-06
- Completion
- 2002-10
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTrachomaIntervention10% permethrin in water applied as low volume sprayPhasePhase 4Registry statusCompletedCocamide DEA vs Permethrin for Head Lice
NCT02500524 · start 1998-07
Registered record
- Registry ID
- NCT02500524
- Conditions
- Pediculosis Capitis; Head Louse Infestation
- Interventions
- Cocamide diethanolamine; Permethrin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 1998-07
- Completion
- 1999-01
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPediculosis Capitis; Head Louse InfestationInterventionCocamide diethanolamine; PermethrinPhasePhase 3Registry statusTerminated